![thyroid thyroid](https://static.packgene.com/wp-content/uploads/2023/06/thyroid.jpg)
Now for the first time, researchers from Boston University Chobanian & Avedisian School of Medicine, have shown that in addition to being critical for regulating thyroid hormone levels, thyrotropin-releasing hormone (TRH) neurons play a major role in the response to fasting and weight loss.
To test this function, the researchers used a chemogenetic approach (engineering of protein receptors to respond to previously unrecognized small molecules) to either stimulate or inhibit specific neuronal populations. They injected an experimental model with an adeno-associated virus (AAV) coding for a mutant receptor activated exclusively by an exogenous compound into specific areas of the brain.
By associating this procedure with genetically modified experimental models, the researchers were able to control the activity of TRH neurons in the paraventricular nucleus of the hypothalamus and of agouti-relate protein/neuropeptide Y (AgRP/NPY) neurons of the arcuate nucleus of the hypothalamus.
“It allowed us to show that TRH neuron suppression and AgRP/NPY neuron activation play a major role in the organism’s response to negative energy balance, such as fasting,” explained corresponding author Anthony Hollenberg, MD, the John Wade Professor of Medicine and chair at the School.
According to the researchers, by controlling the activity of these neurons they were able to change the entire endocrine system related to the thyroid. “Probing deeper into these findings will lead to new knowledge with potential application to metabolic and thyroid-related diseases, such as obesity and central hypothyroidism,” adds Hollenberg, who also is physician-in-chief at Boston Medical Center.
These findings appear online in the journal Thyroid.
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
AAV Packaging - NHP Grade
READ MORE
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
Off the Shelf AAV Products
We offer a wide catalogue of pre-made AAVs for a multitude of research needs.
READ MORE
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
READ MORE